01—Abstract
Summary
Summary of the 10-K/A filed May 5, 1995. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 1994 10-K shows a company in strong growth mode, with net sales rising 22% to $681.9 milliona and net earnings up 20% to $72.4 million, or $1.50 per share.
Much of the top-line expansion was inorganic: the August 1994 consolidation of Matsumoto Medical Instruments, its Japanese distributor, contributed roughly 12 points of the sales increase. Underlying domestic sales grew a more modest 7%b, slowed by uncertainty over U.S. health care reform, while international sales rose 54% and now represent 41% of revenue. Operating margin improved to 17.7% from 16.5%, helped by cost-of-sales gains and lower R&D intensity, though selling, general and administrative expense climbed to 32.5% of sales from 30.9%, reflecting the distributor-heavy Matsumoto cost structure.
The balance sheet changed materially. Total assets nearly doubled to $768.0 millionc, driven by the Matsumoto deal, which was financed largely with yen-denominated bank debt. Long-term debt rose to $95.3 million from $31.3 million, though the interest rate on the principal loans was fixed at 4.17% via swaps and the company still held $202.0 million in cash and marketable securities.
Working capital rose to $361.3 milliond. Accounts receivable and inventories grew faster than sales, with days sales outstanding increasing to 67 from 47, a trend investors should monitor for collection quality. Return on average equity held at a healthy 22.4%.
Looking ahead, the key investor considerations are the durability of growth once the Matsumoto consolidation laps, the sensitivity of domestic medical device demand to health care reform outcomes, and the company's ability to convert its expanded international footprint into sustained margin improvement. The company also disclosed a $152.6 million pool of undistributed foreign earnings intended for indefinite reinvestment overseas, and a 10-year financial history showing consistent compounding of sales and earnings since 1985.
02—Key points
Key Highlights
- Net sales grew 22% to $681.9 million in 1994, with the consolidation of Matsumoto Medical Instruments contributing about 12 percentage points of that increase.
- Net earnings rose 20% to $72.4 million, or $1.50 per share, versus $60.2 million ($1.25 per share) in 1993.
- Operating margin expanded to 17.7% from 16.5%, driven by lower cost of sales (44.0% of sales vs. 46.1%) and reduced R&D intensity.
- International sales increased 54% and reached 41% of total sales, up from 32% in 1993; domestic sales grew only 7% amid health care reform uncertainty.
- Total assets nearly doubled to $768.0 million, and long-term debt increased to $95.3 million from $31.3 million to finance the 51% Matsumoto stake, with the interest rate fixed at 4.17% via swaps.
- Cash and marketable securities of $202.0 million and working capital of $361.3 million provide substantial liquidity; return on average equity was 22.4%.
- Working capital pressure emerged as days sales outstanding rose to 67 from 47 and inventory days rose to 131 from 114, largely reflecting the Matsumoto consolidation.
03—Questions
Frequently Asked Questions
How much of Stryker's 1994 sales growth was organic versus acquired?
The Matsumoto consolidation accounted for about 12 points of the 22% sales increase, other business acquisitions added about 3 points, and higher selling prices contributed about 2 points. Increased unit volume drove roughly 8 points, and the conversion of Osteonics' domestic distribution to direct sales reduced sales by about 3 points. Investors should note that Matsumoto's contribution is a one-time step-up from the August 1994 consolidation rather than a repeatable growth rate.
Why did Stryker's domestic sales slow compared with international sales?
Domestic sales grew only 7% in 1994 because uncertainty over U.S. health care reform slowed purchasing of medical devices. International sales rose 54%, led by Japanese sales from the Matsumoto consolidation and growth in Osteonics orthopaedic implants, Dimso spinal implants, and powered surgical instruments. Management's commentary indicates the domestic slowdown was tied to policy uncertainty rather than a loss of product demand.
Did the Matsumoto acquisition strain Stryker's balance sheet?
The company's balance sheet expanded considerably. Total assets rose to $768.0 million from $454.2 million, and long-term debt increased to $95.3 million from $31.3 million. The debt consists of yen-denominated loans maturing in 1998 whose effective rate was fixed at 4.17% using interest rate swaps. Stryker still held $202.0 million in cash and marketable securities, and about $8.5 million of the purchase price was deferred to April 1995, so liquidity remained strong.
Is Stryker's working capital and receivables management a concern for investors?
Working capital increased to $361.3 million, and the current ratio held at 3.0. However, accounts receivable rose 76% and days sales outstanding increased to 67 from 47, while inventory days rose to 131 from 114. Management attributes these increases mainly to Matsumoto's longer collection terms and higher distributor inventory levels. Investors should watch whether these metrics normalize in 1995, since they affect cash conversion; operating cash flow was still a solid $97.7 million.
What does Stryker's undistributed foreign earnings disclosure mean?
Stryker reported $152.6 million of undistributed earnings from foreign subsidiaries at December 31, 1994, which management expects to reinvest overseas indefinitely. No U.S. or foreign tax provision has been recorded on these amounts, so repatriation would potentially create additional tax liability. Investors should view this as a deferred tax contingency tied to the company's international expansion strategy, particularly given the growing role of Japanese and European operations.
04—Continue